Dental implant manufacturer Straumann Holding AG’s shares fluctuated on Thursday after mixed analyst reactions to its second-quarter results, trading flat near CHF102 despite an intraday high near CHF104.
Deutsche Bank downgraded the stock to Hold from Buy and reduced its price target to CHF99 from CHF119, citing valuation concerns. The bank noted Straumann’s shares were trading at roughly 26 times projected 2027 earnings, a level it deemed stretched. In contrast, JPMorgan maintained an Overweight rating while raising its target to CHF136 from CHF123, underscoring the company’s organic growth trajectory. Barclays and BMO Capital retained constructive ratings but trimmed their targets modestly.
The mixed analyst response followed Straumann’s Q2 performance, which reported organic revenue growth of 8.5%, building on its first-half 2026 results. The company also upgraded its full-year profitability guidance, targeting a core EBIT margin improvement of 140–170 basis points. The stock had declined sharply on August 19 after the release of its half-year results.
Straumann’s leadership transition is scheduled to conclude by year-end, with Guillaume Daniellot stepping down as CEO and Christopher Norbye taking over. The broader U.S. equity market showed modest gains during the session, with the S&P 500 up 0.3% and the Nasdaq advancing 0.5%.
